Showing results (61-70 of 110) with videos related to
Sort By:
Pageof 11
Annals of Translational Medicine|September 2, 2017
Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in ItalyAntonio Tursi, Walter Elisei, Marcello Picchio, et al.European Journal of Internal Medicine|August 4, 2014
Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centersAntonio Tursi, Walter Elisei, Marcello Picchio, et al.European Journal of Internal Medicine|March 18, 2014
Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centresAntonio Tursi, Walter Elisei, Marcello Picchio, et al.Journal of Clinical Gastroenterology|September 14, 2016
Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the ColonAntonio Tursi, Paola Mastromarino, Daniela Capobianco, et al.Clinical Pharmacology and Therapeutics|March 5, 2026
Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative ColitisAntonio Tursi, Andrea Pasta, Walter Elisei, et al.European Journal of Gastroenterology & Hepatology|June 3, 2020
Risk factors for endoscopic severity of diverticular disease of the colon and its outcome: a real-life case-control studyAntonio Tursi, Alessandra Violi, Ginevra Cambie', et al.Journal of Clinical Medicine|November 13, 2025
Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative ColitisAntonio Tursi, Raffaele Pellegrino, Giammarco Mocci, et al.Minerva Gastroenterologica E Dietologica|March 16, 2017
Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centersAntonio Tursi, Leonardo Allegretta, Stefania Chiri, et al.Therapeutic Advances in Gastroenterology|June 18, 2026
An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patientsAntonio Tursi, Andrea Pasta, Walter Elisei, et al.Journal of Immunology Research|June 20, 2015
Interactions between Innate Immunity, Microbiota, and ProbioticsGianMarco Giorgetti, Giovanni Brandimarte, Federica Fabiocchi, et al.Pageof 11